ACU Reports Q2 2026 Earnings Beat Driven by MyMedic Acquisition and Margin Expansion

• Acme United reported Q2 2026 EPS of $1.22, significantly beating estimates of $0.81. Revenue reached $62.7 million versus $58.1 million estimated. Shares surged nearly 12% to near a 52-week high following the release.

• The earnings beat was primarily driven by the integration of MyMedic. This acquisition contributed to a 16% year-over-year sales increase. Excluding the acquisition, organic growth stood at 8%.

• Gross margins improved to 42.6% from 41.0% in the prior year period. Management cited operational efficiencies and favorable product mix as key drivers for continued profitability.

What factors drove Acme United's strong second quarter performance?

Acme United Corporation (ACU) delivered a robust Q2 2026 performance, posting EPS of $1.22 against a forecast of $0.81 and revenue of $62.7 million versus $58.1 million estimated. The stock price responded positively, surging approximately 11.92% to near its 52-week high of $51.88.

The growth trajectory was primarily fueled by the recent acquisition of MyMedic. This integration contributed to a 16% year-over-year increase in total sales. Excluding the impact of acquisitions, the company demonstrated healthy organic growth of 8%.

Financial efficiency also improved significantly. Gross margins expanded to 42.6% from 41.0% in the prior year period . This expansion reflects operational efficiencies and favorable product mix adjustments throughout the quarter .

How is management addressing tariff pressures and future profitability?

Management highlighted that tariff-related cost pressures are expected to ease as the year progresses . Lower-cost inventory is replacing higher-tariff stock, supporting margin recovery . CEO Johnsen indicated that margin recovery is expected to continue throughout the remainder of the year .

The company is actively managing tariff pressures by transitioning from higher-tariff inventory to lower-cost stock . This strategic inventory management is key to sustaining the improved margin trajectory observed in Q2 .

Additionally, the integration of MyMedic is progressing. The company is focusing on expanding the brand's distribution beyond direct-to-consumer channels into mass retail markets . CEO Johnsen noted a strategic focus on expanding distribution into mass retail .

Strong seasonal demand is expected to drive profitability in the fourth quarter . Management projects strong profitability for the fourth quarter, supported by these seasonal demand patterns .

What risks should investors monitor going forward?

Despite the positive results, investors should monitor several risk factors. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales . This elevated expense ratio could impact net profitability if not managed effectively .

The company faces ongoing headwinds from tariffs, freight costs, and currency fluctuations . Potential tariff and freight cost volatility remains a key concern for future margins . Currency headwinds also pose a risk to international operations .

Geographic performance has been uneven, with Canada currently lagging behind other regions . This uneven performance highlights regional disparities in demand and execution . Investors should watch for improvements in the Canadian market as a indicator of broader operational health .

Elevated SG&A expenses represent a persistent challenge. The ratio of 32% of sales requires careful monitoring to ensure it does not erode the gross margin gains achieved . Management must balance growth investments with cost discipline to maintain profitability .

The integration of MyMedic continues to be a focal point. Expanding into mass retail requires significant investment and execution capability . Success in this area will be critical for long-term growth beyond the initial acquisition boost .